Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metabolic rate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    784 result(s) found for: Metabolic rate. Displaying page 1 of 40.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-022308-34 Sponsor Protocol Number: JW/IB/AG Start Date*: 2011-04-19
    Sponsor Name:Central Manchester Foundation Hospitals Trust
    Full Title: Eplerenone in Metabolic Syndrome: An investigation into the effects of Eplerenone on perivascular adipose tissue and small artery tone in obesity
    Medical condition: Obesity and Metabolic Syndrome (combination of obesity, hypertension, raised blood glucose and cholesterol abnormalities)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10052066 Metabolic syndrome PT
    13.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002638-36 Sponsor Protocol Number: 1aa Start Date*: 2020-03-03
    Sponsor Name:Bispebjerg Hospital, University of Copenhagen
    Full Title: Glucagon Dose-response Relationship for Cardiovascular Activity A Randomized, participant-blinded, Crossover Study
    Medical condition: Glucagon-induced changes in heart rate, blood pressure, cardiac output. and metabolic effects
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002222-23 Sponsor Protocol Number: P170932J Start Date*: 2019-02-05
    Sponsor Name:APHP
    Full Title: Cobimetinib for BRAF-wild-type histiocytoses : a randomized, placebo-controlled, double blind study
    Medical condition: Histiocytoses are rare multisystemic disorders characterized by accumulation of histiocytes in various organs. patients with BRAF-wild type.
    Disease:
    Population Age: Gender:
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000540-14 Sponsor Protocol Number: HIGHCARE Start Date*: 2008-05-20
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Role of the renin-angiotensin system in the cardiovascular, metabolic, neurologic and respiratory response to hypobaric hypoxia during sustained exposure to high altitude.
    Medical condition: This study is aimed at the investigation of adaptative physiological mechanisms at high altitude and not at the development of new therapeutic indications.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003430-85 Sponsor Protocol Number: OBERAL Start Date*: 2017-11-29
    Sponsor Name:Helsinki University Hospital
    Full Title: A randomized, open, parallel design study to evaluate the effect on liver fat, adipose tissue and metabolic parameters when switching a protease inhibitor or efavirenz to once daily raltegravir in ...
    Medical condition: Study subjects are HIV infected patients with BMI>25kg/m2 and who have at least one metabolic syndrome component or a fatty liver disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-002095-10 Sponsor Protocol Number: MV-2-2017 Start Date*: 2017-09-13
    Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest
    Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in Chronic Kidney D...
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10027425 Metabolic bone disorders HLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10078095 Chronic kidney disease-mineral and bone disorder PT
    20.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000619-42 Sponsor Protocol Number: PI14/00638 Start Date*: 2015-05-05
    Sponsor Name:FIBICO
    Full Title: An open, Phase II, clinical trial to evaluate the effectiveness of decreased intestinal absorption of phosphorus in the progression of renal disease in patients with metabolic syndrome
    Medical condition: Chronic kidney disease and metabolic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020875-22 Sponsor Protocol Number: MetSNS Start Date*: 2010-08-20
    Sponsor Name:RUNMC
    Full Title: In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS). Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resista...
    Medical condition: Subjects suffer from the metabolic syndrome. Effects of study medication on insulin resistance and vascular function will be studied respectively.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022489 Insulin resistance LLT
    12.1 10052066 Metabolic syndrome LLT
    12.1 10048554 Endothelial dysfunction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002269-21 Sponsor Protocol Number: 01.00240 Start Date*: 2013-12-06
    Sponsor Name:Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto
    Full Title: Metformin in diastolic dysfunction of metabolic syndrome
    Medical condition: Diastolic dysfunction in non-diabetic patients with metabolic syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003606-28 Sponsor Protocol Number: CVAL489ADE25 Start Date*: 2005-10-28
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metaboli...
    Medical condition: patients with hypertension and metabolic syndrome (ATP III)
    Disease: Version SOC Term Classification Code Term Level
    4.0 10052066 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001856-12 Sponsor Protocol Number: NT-12331-5 Start Date*: 2011-08-11
    Sponsor Name:The Motol University Hospital
    Full Title: Early assessment of effectivness of neoadjuvant chemotherapy for carcinoma of the esophagus and esophago-gastric junction using FDG-PET/CT.
    Medical condition: adenocarcinoma of the esophagus and esophago-gastric junction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002140-41 Sponsor Protocol Number: 13171 Start Date*: 2008-11-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: Double-blind, placebo controlled, randomized study of vardenafil to determine efficacy on Erectile Dysfunction (ED) in men with ED and Metabolic Syndrome ("ED-METABOLIC")
    Medical condition: The objective of this study is to determine efficacy, tolerability and safety of vardenafil on Erectile Dysfunction (ED) in men with ED and Metabolic Syndrome.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006677-26 Sponsor Protocol Number: 68797373 Start Date*: 2022-06-22
    Sponsor Name:Maastricht University
    Full Title: Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease
    Medical condition: Healthy volunteers (non-alcoholic fatty liver disease)
    Disease: Version SOC Term Classification Code Term Level
    25.0 10024581 - Lipid metabolism and deposit disorders NEC 10029530 Non-alcoholic fatty liver PT
    25.0 10024581 - Lipid metabolism and deposit disorders NEC 10082249 Nonalcoholic fatty liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002630-17 Sponsor Protocol Number: NBK132/2/2021 Start Date*: 2022-02-02
    Sponsor Name:Medical Unicersity of Gdansk
    Full Title: Treatment of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and Dexamethasone (BGD) with autologous bone marrow transplantation in lymphoma patients Hodgkin resistant to treatmen...
    Medical condition: Refractory / relapsed Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005032-42 Sponsor Protocol Number: 17-162 Start Date*: 2020-04-20
    Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty
    Full Title: Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease
    Medical condition: Diabetes Type 2 with existing cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004123-19 Sponsor Protocol Number: MUN-391-LOR-0050-I Start Date*: 2006-01-24
    Sponsor Name:Klinikum rechts der Isar der Technischen Universitaet Muenchen
    Full Title: Metabolic Response Evaluation for an Individualization of Neoadjuvant Chemo- and Radiotherapy in Esophageal Adenocarcinoma
    Medical condition: This study will test an optimized therapy for patients with chemotherapy-resistent locally advanced adenocarcinomas at the gastro-esophageal junction. According to the protocol, patients should re...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000624-16 Sponsor Protocol Number: LOEWE_B4 Start Date*: 2011-11-28
    Sponsor Name:Justus Liebig Universität Gießen
    Full Title: Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome Male infertility with infection and inflammation -MIBIE-
    Medical condition: infertility and inflammatory urogenital diseases as a result of the metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10046694 Urogenital disorder PT
    14.0 10027433 - Metabolism and nutrition disorders 10052066 Metabolic syndrome PT
    14.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002472-16 Sponsor Protocol Number: CCD09 Start Date*: 2011-12-19
    Sponsor Name:Cytonet GmbH & Co KG
    Full Title: Open, prospective, diagnostic, multicentre study in healthy subjects, patients with urea cycle disorders (UCD), and carriers of UCD mutations, to evaluate in vivo ureagenesis measured after a singl...
    Medical condition: 1. Healthy subjects 2. Symptomatic UCD patients with genetically confirmed CPSD, OTCD, ASSD, or ASLD 3. Asymptomatic carriers of UCD mutations (e.g. parents)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005121-21 Sponsor Protocol Number: THEROS Start Date*: 2018-11-13
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabol...
    Medical condition: Non-small-cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2005-000614-12 Sponsor Protocol Number: CV131-186 Start Date*: 2005-11-28
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome. Irbesartan en el tratamiento del paciente hipertenso con síndrome metabólico
    Medical condition: Hypertension, nos
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 31 07:04:31 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA